Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 + 464 word(s) 464 2020-12-15 07:18:34

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Yang, C. CLN7 Disease. Encyclopedia. Available online: (accessed on 19 June 2024).
Yang C. CLN7 Disease. Encyclopedia. Available at: Accessed June 19, 2024.
Yang, Catherine. "CLN7 Disease" Encyclopedia, (accessed June 19, 2024).
Yang, C. (2020, December 24). CLN7 Disease. In Encyclopedia.
Yang, Catherine. "CLN7 Disease." Encyclopedia. Web. 24 December, 2020.
CLN7 Disease

CLN7 disease is an inherited disorder that primarily affects the nervous system. The signs and symptoms of this condition typically begin between ages 2 and 7. The initial features usually include recurrent seizures (epilepsy) and the loss of previously acquired skills (developmental regression). Affected children also develop muscle twitches (myoclonus), difficulty coordinating movements (ataxia), speech impairment, and vision loss. Mental functioning and motor skills (such as sitting and walking) decline with age. Individuals with CLN7 disease typically do not survive past their teens.

genetic conditions

1. Introduction

CLN7 disease is one of a group of disorders known as neuronal ceroid lipofuscinoses (NCLs), which may also be collectively referred to as Batten disease. All these disorders affect the nervous system and typically cause worsening problems with vision, movement, and thinking ability. The different NCLs are distinguished by their genetic cause. Each disease type is given the designation "CLN," meaning ceroid lipofuscinosis, neuronal, and then a number to indicate its subtype.

2. Frequency

The incidence of CLN7 disease is unknown; more than 70 cases have been described in the scientific literature. CLN7 disease was first diagnosed in the Turkish population and was thought to be limited to individuals in that group. However, CLN7 disease has now been identified in people around the world. Collectively, all forms of NCL affect an estimated 1 in 100,000 individuals worldwide.

3. Causes

Mutations in the MFSD8 gene cause CLN7 disease. The MFSD8 gene provides instructions for making a protein whose function is unknown. The MFSD8 protein is embedded in the membrane of cell compartments called lysosomes, which digest and recycle different types of molecules. Based on the structure of the protein, MFSD8 probably transports molecules across the lysosomal membrane, but the specific molecules it moves have not been identified.

MFSD8 gene mutations likely lead to the production of a protein with altered structure or function. It is unclear how an altered MFSD8 protein leads to the severe neurological features of CLN7 disease. CLN7 disease, like other NCLs, is characterized by the accumulation of proteins and other substances in lysosomes. These accumulations occur in cells throughout the body; however, nerve cells seem to be particularly vulnerable to their effects. These accumulations can cause cell damage leading to cell death. Individuals with CLN7 disease have gradual nerve cell loss in certain parts of the brain, which likely leads to the signs and symptoms of this condition.

4. Inheritance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

5. Other Names for This Condition

  • CLN7
  • CLN7 disease, late infantile
  • MFSD8-related neuronal ceroid lipofuscinosis


  1. Craiu D, Dragostin O, Dica A, Hoffman-Zacharska D, Gos M, Bastian AE,Gherghiceanu M, Rolfs A, Nahavandi N, Craiu M, Iliescu C. Rett-like onset inlate-infantile neuronal ceroid lipofuscinosis (CLN7) caused by compoundheterozygous mutation in the MFSD8 gene and review of the literature data onclinical onset signs. Eur J Paediatr Neurol. 2015 Jan;19(1):78-86. doi:10.1016/j.ejpn.2014.07.008.
  2. Kollmann K, Uusi-Rauva K, Scifo E, Tyynelä J, Jalanko A, Braulke T. Cellbiology and function of neuronal ceroid lipofuscinosis-related proteins. Biochim Biophys Acta. 2013 Nov;1832(11):1866-81. doi: 10.1016/j.bbadis.2013.01.019.
  3. Kousi M, Siintola E, Dvorakova L, Vlaskova H, Turnbull J, Topcu M, Yuksel D,Gokben S, Minassian BA, Elleder M, Mole SE, Lehesjoki AE. Mutations in CLN7/MFSD8are a common cause of variant late-infantile neuronal ceroid lipofuscinosis.Brain. 2009 Mar;132(Pt 3):810-9. doi: 10.1093/brain/awn366.
  4. Sharifi A, Kousi M, Sagné C, Bellenchi GC, Morel L, Darmon M, Hulková H, RuivoR, Debacker C, El Mestikawy S, Elleder M, Lehesjoki AE, Jalanko A, Gasnier B,Kyttälä A. Expression and lysosomal targeting of CLN7, a major facilitatorsuperfamily transporter associated with variant late-infantile neuronal ceroidlipofuscinosis. Hum Mol Genet. 2010 Nov 15;19(22):4497-514. doi:10.1093/hmg/ddq381.
  5. Siintola E, Topcu M, Aula N, Lohi H, Minassian BA, Paterson AD, Liu XQ, WilsonC, Lahtinen U, Anttonen AK, Lehesjoki AE. The novel neuronal ceroidlipofuscinosis gene MFSD8 encodes a putative lysosomal transporter. Am J HumGenet. 2007 Jul;81(1):136-46.
  6. Williams RE, Mole SE. New nomenclature and classification scheme for theneuronal ceroid lipofuscinoses. Neurology. 2012 Jul 10;79(2):183-91. doi:10.1212/WNL.0b013e31825f0547.
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to :
View Times: 355
Entry Collection: MedlinePlus
Revision: 1 time (View History)
Update Date: 24 Dec 2020
Video Production Service